HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

fms-Like Tyrosine Kinase 3

Subscribe to New Research on fms-Like Tyrosine Kinase 3

A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.

Also Known As:

CD135 Antigen; Fetal Liver Kinase-2; Fetal Liver Kinase-3; Stem Cell Tyrosine Kinase 1; Antigen, CD135; Fetal Liver Kinase 2; Fetal Liver Kinase 3; fms Like Tyrosine Kinase 3; Antigens, CD135; CD135 Antigens

Networked: 223 relevant articles (8 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Small, Donald: 11 articles (06/2015 - 03/2004)
2.	Castro, Maria G: 11 articles (09/2013 - 12/2004)
3.	Lowenstein, Pedro R: 11 articles (09/2013 - 12/2004)
4.	Liu, Chunyan: 9 articles (10/2011 - 12/2004)
5.	Levis, Mark: 8 articles (06/2015 - 03/2004)
6.	Candolfi, Marianela: 7 articles (10/2012 - 07/2007)
7.	Kantarjian, Hagop: 6 articles (07/2014 - 05/2004)
8.	Ravandi, Farhad: 6 articles (07/2014 - 01/2011)
9.	Levis, Mark J: 5 articles (07/2015 - 11/2006)
10.	Li, Li: 5 articles (06/2015 - 03/2004)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2010 - "Molecular characterization of the FMS-like tyrosine kinase 3 receptor (FLT3) in cytogenetically normal acute myeloid leukemia (AML) has recently been incorporated into clinical guidelines based on correlations between FLT3 internal tandem duplications (FLT3-ITD) and decreased disease-free and overall survival. " 10/01/2011 - "The aim of this study was to analyze the FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) allelic ratios (AR), number of ITD, ITD length and positions of ITD insertions in de novo acute myeloid leukemia (AML) patients with FLT3-ITD positive, and the relationship between mutant level and therapeutic efficacy. " 01/01/2010 - "This study revealed that approximately 30% of acute myeloid leukemia patients have either KIT or fms-like tyrosine kinase 3 genetic mutations. " 01/01/2009 - "FLT3 (fms-like tyrosine kinase 3) is frequently activated by mutation in acute myeloid leukemia, and is therefore under study as a drug target. " 09/01/2015 - "Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. "
2.	Neoplasms (Cancer) 04/15/2015 - "An improved understanding of how the signaling pathways [e.g., Fms-like tyrosine kinase 3 (Flt3), PI3K, and signal transducer and activator of transcription (Stat)] are dysregulated by these mutations in Cbl has helped to identify potential targets for therapy of myeloid neoplasms. " 12/01/2011 - "In the present study, we sought to increase the number of tumor-associated dendritic cells (DC) in vivo and tumor antigen presentation by combining VSV treatment with recombinant Fms-like tyrosine kinase 3 ligand (rFlt3L), a growth factor promoting the differentiation and proliferation of DC. " 04/01/2005 - "We report that transfection of 4T1 mammary tumor cells (p53-null) with the dendritic cell (DC) growth factor, fms-like tyrosine kinase 3 ligand (Flt3L), significantly delayed their growth in vivo, resulting in the rejection of 100% of the tumors formed by injection of tumor cells cotransfected with Flt3L and p53. " 02/01/2008 - "Systemic administration of Fms-like tyrosine kinase 3 ligand (FLT3L) has been considered to be a major route of delivery for tumor immunotherapy because expression of its receptor, FLT3, was detected predominantly in hematopoetic progenitor cells. " 12/01/2013 - "Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model."
3.	Lung Injury 11/01/2012 - "Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice." 11/01/2012 - "In the present study, we examined the effects of in vivo Fms-like tyrosine kinase 3 ligand (Flt3L) treatment on zymosan (zym)-induced secondary lung injury and dendritic cell (DC) immunoparalysis. "
4.	Thrombocytopenia (Thrombopenia) 08/01/2015 - "Pacritinib, a JAK2 and FMS-like tyrosine kinase 3 (FLT3) inhibitor, has shown promising results in early phase trials with limited myelotoxicity and clinical responses that are comparable with those seen with ruxolitinib, even in patients with severe thrombocytopenia. "
5.	Leukemia 03/06/2014 - "We found that IDH2(R140Q) can cooperate with overexpression of HoxA9 and Meis1a and with mutations in FMS-like tyrosine kinase 3 (FLT3) to drive acute leukemia in vivo. " 01/01/2014 - "Another such possible target in pediatric acute leukemia is FMS-like tyrosine kinase 3 (FLT3). " 09/01/2011 - "The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias. " 01/01/2011 - "FMS-like tyrosine kinase 3 (FLT3) is a commonly mutated protein in a variety of human acute leukemias. " 03/01/2010 - "Gene expression profiling experiments identified putative downstream MN1 targets, of which FMS-like tyrosine kinase 3 (FLT3) and CD34 were upregulated in both MN1-overexpressing murine leukemias and in pediatric acute leukemias with high MN1 levels. "

Related Drugs and Biologics

1.	Protein-Tyrosine Kinases (Tyrosine Kinase)
2.	sorafenib (BAY 43-9006)
3.	Phosphotransferases (Kinase)
4.	Zymosan
5.	INCB018424
6.	nucleophosmin
7.	Janus Kinase 2
8.	Etoposide (VP 16)
9.	Type II DNA Topoisomerases (Topoisomerase II)
10.	PKC412

Related Therapies and Procedures

1.	Hematopoietic Stem Cell Transplantation
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Transplants (Transplant)
5.	Aftercare (After-Treatment)